Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of cemdisiran (ALN-CC5) in adult patients with atypical hemolytic uremic syndrome
2017-001082-24Phase 2Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jun 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of cemdisiran in atypical hemolytic uremic syndrome (aHUS), hemolytic uremic syndrome (HUS), sponsored by Alnylam Pharmaceuticals. Started Jun 2017; status: terminated.
02
Drugs
cemdisiran
03
Conditions
atypical hemolytic uremic syndrome (aHUS)hemolytic uremic syndrome (HUS)
Beyond the preview
Go deeper on 2017-001082-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001082-24.